Rebecca L Jensen
Overview
Explore the profile of Rebecca L Jensen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
15
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bevers L, Jensen R, Owen A, Colbers A, Carr D, Burger D
Pharmacogenomics
. 2024 Dec;
25(14-15):623-635.
PMID: 39697075
Background: Dolutegravir (DTG) is an antiviral agent used for the treatment of HIV, however, there is uncertainty over the influence of genetic variation on DTG exposure, and whether it has...
2.
Ogiji E, Aboheimed N, Ross K, Voller C, Siner R, Jensen R, et al.
Curr Opin Allergy Clin Immunol
. 2024 May;
24(4):218-227.
PMID: 38753537
Purpose Of Review: Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) are severe cutaneous adverse drug reactions (SCARs) characterized by widespread epithelial detachment and blistering, which affects the skin and mucocutaneous membranes. To...
3.
Heaton B, Jensen R, Line J, David C, Brain D, Chadwick A, et al.
Biomed Pharmacother
. 2022 Apr;
150:112999.
PMID: 35461087
SLC2A1 mediates glucose cellular uptake; key to appropriate immune function. Our previous work has shown efavirenz and lopinavir exposure inhibits T cell and macrophage responses, to known agonists, likely via...
4.
Hanley A, Bernstein A, Nakamura Y, Hadash Y, Rojas J, Tennant K, et al.
Psychol Assess
. 2020 Jul;
32(10):956-971.
PMID: 32700920
The ability to decenter from internal experiences is important for mental health. Consequently, improving decentering is a common therapeutic target, particularly for mindfulness-based interventions. However, extant decentering measures are limited...
5.
Penman S, Kiy R, Jensen R, Beoku-Betts C, Alfirevic A, Back D, et al.
Br J Pharmacol
. 2020 Jul;
177(19):4353-4374.
PMID: 32681537
Intense efforts are underway to evaluate potential therapeutic agents for the treatment of COVID-19. In order to respond quickly to the crisis, the repurposing of existing drugs is the primary...
6.
Penman S, Jensen R, Kiy R, Chadwick A
Elife
. 2020 Jun;
9.
PMID: 32583799
A structural motif that is found in two cancer drugs may be responsible for their ability to tackle cancers and for the side-effects caused by the drugs.